The Notch signaling pathway is an evolutionarily conserved transduction pathway involved in embryonic patterning and regulation of cell fates during development. Recent studies have demonstrated that this pathway is integral to a complex system of interactions, which are also involved in distinct human diseases. Delta1 is one of the known ligands of the Notch receptors. Mice homozygous for a loss-offunction allele of the Delta1 gene Dll1 lacZ/lacZ die during embryonic development. Here, we present the results of two phenotype-driven modifier screens. Heterozygous Dll1 lacZ knockout animals were crossed with ENU-mutagenized mice and screened for dysmorphological, clinical chemical, and immunological variants that are dependent on the Delta1 loss-of-function allele. First, we show that mutagenized heterozygous Dll1 lacZ offspring have reduced body weight and altered specific clinical chemical parameters, including changes in metabolites and electrolytes relevant for kidney function. In our mutagenesis screen we have successfully generated 35 new mutant lines. Of major interest are 7 mutant lines that exhibit a Dll1 lacZ/1 -dependent phenotype. These mutant mouse lines provide excellent in vivo tools for studying the role of Notch signaling in kidney and liver function, cholesterol and iron metabolism, cell-fate decisions, and during maturation of T cells in the immune system.
T HE Notch signaling pathway is an intercellular signaling mechanism that is highly conserved during evolution. It is involved in the determination of cell fates in different cell types of metazoan development. The phenotype caused by Notch gene mutation was first observed almost 90 years ago in Drosophila melanogaster as a notched wing (Artavanis-Tsakonas et al. 1999) . Complete loss of function of the Notch gene leads to a lethal phenotype in flies; cells destined to become epidermis switch their fate and give rise to neural tissue. Genes encoding Notch orthologs have been cloned and characterized in several organisms. In mammals, four distinct Notch genes have been identified, Notch1-4 (Ellisen et al. 1991; Weinmaster et al. 1992; Lardelli et al. 1994; Uyttendaele et al. 1996) . The Notch receptors are anchored to the plasma membrane via a single transmembrane domain. Two families of transmembrane ligands interact with the Notch receptors: the Delta and the Jagged/Serrate class of gene products (Kadesch 2004) . In mammals, the Delta family encompasses three proteins, Delta1, Delta3, and Delta4 (Bettenhausen et al. 1995; Dunwoodie et al. 1997; Shutter et al. 2000) , and the Jagged/Serrate family consists of two ligands, Jagged1 and Jagged2 (Lindsell et al. 1995; Shawber et al. 1996) . The canonical Notch pathway involves two distinct proteolytic processing events that cleave the Notch receptors in response to ligand activation. This eventually leads to the release of the Notch intracellular domain (NICD) into the cytoplasm (Kadesch 2004) . NICD is subsequently translocated to the nucleus, where it interacts with the transcriptional regulator CBF, Su(H), Lag-2 (CSL) ( Jarriault et al. 1995) , converting CSL from a repressor to an activator and leading to the transcription of a variety of target genes, including members of the Hes and HRT/HERP/Hey families of transcriptional repressors. These genes encode basic helix-loop-helix transcriptional factors that downregulate the expression of Notch target genes influencing numerous biological processes (Kadesch 2004; Bianchi et al. 2006 ). Loss-or gain-of-function mutations of the receptors or ligands of the Notch signaling pathway have several clinical, physiological, and biological consequences in humans (Harper et al. 2003) . For example, cancer-like T-cell acute lymphoblastic leukemia [Online Mendelian Inheritance in Man (OMIM) no. 190198 ] is associated with mutations in Notch1 (Ellisen et al. 1991) ; cerebral arteriopathy autosomal dominant with subcortical infarcts and leukoencephalopathy (CADASIL; OMIM no.125310), a neurological disease, is associated with mutations in Notch3 ( Joutel et al. 1996) ; Alagille syndrome (OMIM no. 118450), a developmental disease, is associated with mutations in Jagged1 (Li et al. 1997; Oda et al. 1997) ; and spondylocostal dysostosis (OMIM no. 277300), leading to severe congenital malformations of the vertebral column, is associated with mutations in Delta3 (Bulman et al. 2000) .
The above-described canonical linear representation of Notch activity is a simplified model as the full pathway is integrated into a complex system of regulatory interactions with pleiotropic functions. For example, recent studies indicate that not only the intracellular domain of the Notch receptor interacts with other proteins, but also the ICD of the ligands Jagged1 and Delta1 (LaVoie and Selkoe 2003; Pfister et al. 2003 ) may initiate transduction cascades in the ligand-expressing cells. After proteolytic processing of the receptor, the released extracellular domain of Notch, moreover, may undergo endocytosis in the ligand-expressing cell (Parks et al. 2000) or may interact with proteins such as MAGP-2 to initiate a separate signaling cascade (Miyamoto et al. 2006) . Moreover, Notch may function independently of CSL proteins (Martinez Arias et al. 2002; Bianchi et al. 2006) or through interaction with other pathways such as TGFb signaling (Kluppel and Wrana 2005) . Other branches in the canonical signaling pathway have been described and more still remains to be elucidated.
One way to identify either direct or indirect participants in a molecular network or biological process is to perform genetic modifier screens. These already have proven to be highly efficient in the fly and recently also in the mouse (Cormier et al. 2000; Carpinelli et al. 2004; Curtis 2004; Murcia et al. 2004; Speca et al. 2006) . N-ethyl-N-nitrosourea (ENU) mutagenesis has been used as a powerful tool for the establishment of mutant mouse lines that model diseases and for the elucidation of protein function Nolan et al. 2000) . One of the main advantages of ENU mutagenesis is the generation of point mutations that result in functional changes ranging from hypomorphic to full loss of function to hypermorphic alleles. These often provide more functional information and are usually more relevant for human diseases than classical knockouts where the function of a gene is usually completely eliminated (Balling 2001) . Therefore, we are running a phenotype-driven dominant modifier screen by mating ENU-mutagenized mice with Delta1 heterozygous animals to discover novel modifier alleles of the Notch signaling pathway. The Delta1 knockout mouse line was previously generated by replacing amino acids 2-116 with an in-frame fusion of the LacZ gene of Escherichia coli (Hrabe de Angelis et al. 1997) . Delta1 loss of function resulted in developmental lethality before 12.5 days postcoitum. Delta1-deficient embryos showed deficits in epithelialization and compartmentalization of somites and excessive neuronal differentiation. Furthermore, Delta1-deficient embryos showed alterations in cell-fate determination in the developing pancreas (Apelqvist et al. 1999) and in the determination of left-right asymmetry in mice . Conditional ablation of Delta1 function in lymphoid tissue has revealed its importance for the generation of marginal B cells but not for T cells (Hozumi et al. 2004) . Selective loss of Delta1 function in the developing ear resulted in an early and excessive development of auditory hair cells (Brooker et al. 2006) . Recently, it has been demonstrated that Delta1 heterozygous mice show homeotic transformations in the cervical region in vertebral identities with incomplete penetrance (Cordes et al. 2004) . Here, we report that heterozygous Delta1 lossof-function animals show additional variant phenotypes, including alterations in clinical chemical parameters; and these effects are dependent on the genetic background of the animals. Moreover, heterozygous Dll1 lacZ animals display a significantly reduced body weight. In our dominant modifier genetic screen we are searching for novel variants with new mutant phenotypes that are dependent on the Delta1 modified allele. We cover a broad spectrum of phenotypes by analyzing several dysmorphological, clinical chemical, and immunological parameters. At present seven Delta1-dependent heritable mutant phenotypes have been identified, all of which are co-inherited with a single Dll1 lacZ allele and undetectable in the Dll1
background. These novel mouse mutant lines will provide important information about modifiers of Delta1 signaling and the extended Notch pathway.
MATERIALS AND METHODS

Animals:
Mice were housed and handled according to the federal animal welfare guidelines and all the animal studies were approved by the state ethics committee. For this study we used C57BL/6J mice provided by Charles River (Wilmington, MA) and mice carrying the Dll1 lacZ allele (Dll1 tm1Gos ) (Hrabe de Angelis et al. 1997) on an 129X1/SvJ background, formerly 129/SvJ. Our internal name for this line is iso129X1. C57BL/ 6J male mice 10-14 weeks old were mutagenized by injection with 80 mg/kg body-weight ENU (Serva) applied intraperitoneally in three weekly doses. We performed a dominant screen on F 1 animals derived from mutagenized C57BL/6J males crossed with heterozygous Dll1 lacZ females. A minor-scale dominant screen was performed on the iso129X1 background. We injected 24-32 g heterozygous Dll1 lacZ iso129X1 male mice intraperitoneally with four weekly doses of 50 mg/kg body weight ENU (Serva). The animals were mated to wild-type iso129X1 female mice. Breeding pairs where the first F 1 offspring came from conceptions ,60 days after ENU injection were discarded to ensure that only F 1 offspring derived from ENU-exposed spermatogonal stem cell stages were analyzed for phenotyping (Soewarto et al. 2003) . F 1 animals were genotyped and phenotyped as described below. We tested the inheritance of a phenotype by backcrossing the F 1 variants to heterozygous Dll1 lacZ mice. According to the binomial distribution (Gardner 1991) , we determined with a 99.6% probability that we could isolate a mutant if we screened at least eight heterozygous Dll1 lacZ G 2 mice. Moreover, this strategy implies the isolation of phenotypes with at least 25% penetrance, which realistically enables the maintenance and further analysis of the mutant lines. Therefore, we screened at least eight heterozygous Dll1 lacZ G 2 mice and eight Dll1 1/1 littermates and defined a line as Delta1 dependent if the phenotype was transmitted only to the heterozygous Dll1 lacZ mice. Confirmed mutant lines were given names for internal use only and do not reflect official nomenclature. Mutant lines derived from our screen will be assigned with official gene symbols and names in the near future.
Genotyping: At weaning age, $0.2-cm tail clips were gained from the animals to genotype following standardized procedures. Tail-clip samples were incubated overnight in a lysis buffer (10 mm Tris-HCl, pH 8.0, 1% (w/v) SDS, 50 mm EDTA, and 300 mg/ml proteinase K) at 57°. DNA was extracted using the Tecan Freedom Evo 150 Liquid Handling Robot and the AGOWA mag maxi DNA isolation kit. Animals were genotyped by biplex polymerase chain reaction using the primers DLL1FP 59-CAAGGGCGTCCAGCGGTAC-39 (which binds immediately upstream of the Delta1 translation initiation codon) and DLL1BP 59-CCTTGCTAGGACGCAGAGGC-39 (which binds in exon 2), which detect a 459-bp fragment indicative of the wild-type allele, and primers Dll1FP and LacZ3BP GCACCACAGATGAAACGCCG, which detect a 222-bp fragment indicative of the mutated allele.
For linkage analysis, a genomewide mapping panel consisting of 149 single nucleotide polymorphism (SNP) markers was applied. SNPs were retrieved by using a web-based tool (ARTS; Klaften and Hrabe de Angelis 2005) and designed to be polymorphic between strains C3H/He and C3H/HeJ as a reference and BALB/cByJ and C57BL/6J for outcrossing to map the mutations generated in the Munich genomewide mutagenesis screen. Genotyping of this panel was performed using MassExtend, a matrix-assisted laser desorption/ionization time-of-flight high-throughput genotyping system supplied by Sequenom.
Dysmorphological screen: We screened the F 1 animals at weaning and again at 11 weeks of age with slight modifications of the Munich genomewide mutagenesis protocol, as described elsewhere . We screened for body size, body shape, right-left abnormality, skull shape, vibrissae, tooth length, tooth shape, ear size, ear form, eye size, cataracts, limbs, double digits, crippled digits, syndactylism, nails, coiled tail, general physical condition, weight, coat structure, skin color, skin structure, swellings, carcinoma/tumors, strength, gait, trembling, cramping, paralysis, seizures, respiration, general behavior, activity, aggressiveness, exploring, head tossing, head shaking, circling, landing behavior, articulation, social structure in cage, cage cleanliness, urine, and feces. The weight of the animals was determined at 6, 8, 10, and 12 weeks of age. Selected animals were analyzed with the Faxitron Specimen Radiography system model MX-20 for skeletal malformations or with the Norland-Stratec pDEXA peripheral Dual Energy X-ray between 16 and 20 weeks of age for bone density alterations.
Blood samples: We obtained blood samples (300 ml) from 12-week-old mice that had fasted overnight by puncturing the retro-orbital sinus under ether anesthesia (Hrabe de Angelis et al. 2000). We analyzed for clinical chemical, basic hematology, and immunological parameters in the German Mouse Clinic at the GSF Research Center (Gailus-Durner et al. 2005) . A total of 17 clinical chemical parameters were ascertained, namely sodium, potassium, chloride, calcium, inorganic phosphorus, total protein, creatinine, urea, cholesterol, triglycerides, aspartate aminotransferase (AST/GOT), alanine aminotransferase (ALT/GPT), alkaline phosphatase, glucose, ferritin, transferring, and lipase, as previously described (Klempt et al. 2006) . The hematology parameters analyzed included white blood cell count, red blood cell count, hematocrit, hemoglobin, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, and platelets. Additionally, the blood samples were fractionated to perform flow cytometry and ELISA analyses as described elsewhere (Kalaydjiev et al. 2006) . The panel of immunological parameters consisted of CD41 T cells, CD81 T cells, g/d T cells, B cells (B1, B2), natural killer (NK) cells, granulocytes, monocytes, and IgM, IgG 1 , IgG 2a , IgG 2b , IgG 3 , IgA, rheumatoid factor, and anti-DNA antibodies. Furthermore, all potential subpopulations that can be identified by costaining for other surface markers (IgD, B220, CD11b, MHC II, I-Ak, CD25, CD8, CD62L, CD45RA, Ly-6C, CD44) using six parameter/five color flow cytometry were analyzed.
Statistical analysis: Analysis was performed using either the software package JMP Release 5.1 (SAS Institute) or the R Version 1.12 for Mac OS X provided by the R Foundation of Statistical Computing. Outliers defined as those falling outside the 25th or 75th quantile and 1.5 times the interquantile range were discarded. The distribution of the samples was assessed using the Shapiro-Wilk normality test. If required, logarithmic transformation of the data set was performed. The variances and the means of two samples were compared using the Levene test and the two-sample t-test, respectively. Descriptive data are expressed as mean 6 standard deviation. Variants were defined as F 1 animals showing at least one parameter differing three standard deviations from the mean template, i.e., showing a Z-score between .3 and ,À3. Every 2-3 months $250 randomly selected F 1 samples were analyzed and a new template was generated to take into account variation due to environmental conditions already described in clinical chemical parameters (Klempt et al. 2006) .
RESULTS
ENU mutagenesis screens for modifiers of the Delta1 phenotype: At least two breeding strategies have successfully been employed in genomewide mutagenesis programs. Mutagenized males can be crossed either to females with a different genetic background (Nolan et al. 2000) or to females with the same genetic background (Hrabe de Angelis et al. 2000). The first method has the advantage of speeding up the mapping process to identify mutations causing a variant phenotype. The second strategy makes the phenotyping more robust, as the contribution of genetic background in all progeny under study is kept constant. Therefore, we carried out both breeding strategies to screen for modifiers of the Delta1-dependent Notch signaling pathway. In the first strategy, F 1 animals were derived from mutagenized C57BL/6J males crossed to heterozygous Dll1 lacZ females in an iso129X1 background (Hrabe de Angelis et al. 1997), and in the second strategy, F 1 animals were derived from mutagenized heterozygous Dll1 lacZ iso129X1 males crossed to wild-type females of the same genetic background (Figure 1 ). A total of 234 C57BL/6J mice were injected with 80 mg/kg ENU in three weekly doses. Each of the 92 ENU-injected males (39%) generated between 1 and 65 F 1 offspring that underwent the phenotyping work flow. Twelve ENU-treated males (5%) were excluded as the period between the last injection and the calculated time of conception was ,60 days, and therefore the probability of these F 1 animals being derived from mutagenized spermatogonal stem cells was low (Soewarto et al. 2003) . Moreover, 84 ENUinjected males (36%) were sterile or did not produce viable offspring. Likewise, a total of 188 heterozygous Dll1 lacZ mice were injected with 50 mg/kg ENU in four weekly doses. Sixty-three ENU males (33%) generated between 1 and 27 F 1 animals that underwent the phenotyping work flow (see Figure 1) . A total of 125 ENU males were discarded because the sterility period was ,60 days, they were sterile, or they did not produce any living offspring.
Delta1 heterozygous mutant phenotypes: To be able to identify ENU-modified phenotypes from original
Dll1
lacZ/1 phenotypes, we characterized the phenotype of adult heterozygous Delta1 loss-of-function mice in detail. As described previously, homozygous Dll1 lacZ mice die during embryogenesis (Hrabe de Angelis et al. 1997), and a cervical vertebrae phenotype has been described in heterozygous Dll1 lacZ animals (Cordes et al. 2004) . We found the F 1 heterozygous Dll1 lacZ animals to be significantly lighter than their wild-type littermates (Figure 2 ). The data in Figure 2 are for F 1 animals, i.e., the offspring of mutagenized males. Reduction of body weight in the heterozygous Dll1 lacZ animals is more pronounced in male than in female mice, but is detectable in both genders and also increases with age. These differences in body weight are also detectable in the heterozygous Dll1 lacZ iso129X1 F 1 animals when compared to their wild-type littermates (data not shown); therefore the genetic background is not important for this mutant phenotype.
At 12 weeks of age blood samples were taken from the animals by puncturing the retro-orbital sinus and several clinical chemical parameters were analyzed, as described in materials and methods. Almost half of the clinical chemistry parameters were significantly altered in the F 1 heterozygous Dll1 lacZ animals compared to their wild-type littermates (Table 1) . For example, serum activities of aspartate and alanine aminotransferase (AST and ALT) were increased in heterozygous Dll1 lacZ animals compared to their wild-type littermates, although the difference was significant only in males. Plasma chloride and creatinine concentrations were significantly iso129X1 males were injected with three weekly doses of 80 mg/kg body weight or 4 weekly doses of 50 mg/kg body weight, respectively. Mutagenized C57BL/6J males were crossed to heterozygous Dll1 lacZ/1 iso129X1 females, and mutagenized heterozygous Dll1 lacZ/1 iso129X1 males were crossed to wild-type iso129X1 females. The F 1 animals underwent the phenotyping work flow depicted below; boxes with dark shading indicate the time point at which each assay was performed. Interesting heterozygous Dll1 lacZ/1 F 1 variants were tested for inheritance of the phenotype by backcrossing to Dll1 lacZ/1 iso129X1 animals. G 2 animals were then phenotyped.
Figure 2.-Body-weight comparison between heterozygous Dll1 lacZ/1 F 1 animals and their wild-type littermates. Body weight was measured at 6, 8, 10, and 12 weeks of age. All offspring are derived from mutagenized C57BL/6J males and heterozygous Dll1 lacZ/1 females. Depicted are the mean 6 standard deviation from wild-type F 1 males (d, n ¼ 288), heterozygous Dll1 lacZ/1 F 1 males (nnn, n ¼ 324), wild-type F 1 females (n, n ¼ 277), and heterozygous Dll1 lacZ/1 F 1 females (ddd, n ¼ 299). A two-sample t-test was performed comparing the weight of the animals at different ages between wild-type and heterozygous F 1 animals for male and females. P-values: ***P , 0.001, **P , 0.01, *P , 0.05. decreased in both male and female heterozygous Dll1 lacZ animals. In the iso129X1 background, 65% of the examined parameters were significantly altered and most of them showed the tendency to be decreased except for ALT and AST (Table 2 ). All these differences were of course taken into account when screening for ENUinduced phenotypic variants in the dominant modifier screens. The genetic background of a mouse strain has All F 1 offspring were derived from mutagenized C57BL/6J and heterozygous Dll1 lacZ females. a P-value from two-sample t-test: ***P , 0.001, **P , 0.01, *P , 0.05.
TABLE 2
Comparison of clinical chemical parameters between male F 1 animals depending on their genetic background lacZ -iso129X1 males and iso129X1 females. c P-value from two-sample t-test: ***P , 0.001, **P , 0.01, *P , 0.05. strong influence on clinical parameters (see Mouse Phenome Database at the Jackson Laboratory: http:// aretha.jax.org/pub-cgi/phenome/mpdcgi?rtn¼docs/ home). As seen in Table 2 , .75% of the clinical chemical parameters that were identified as components of the Dll1 lacZ/1 phenotype were significantly different compared to the F 1 animals derived from mutagenized C57BL/6J or heterozygous Dll1 lacZ iso129X1 males. Therefore, when phenotyping for variants, different reference values were used, depending on the appropiate genetic background. In male animals, only creatinine and AST were influenced by the genotype, but not by the genetic background investigated.
iso129X1 genetic background: The dysmorphology protocol was designed to screen C3HeB/FeJ animals in the Munich ENU genomewide mutagenesis screen Hrabe de Angelis et al. 2000) . We had to modify this protocol as described in materials and methods, as some of the parameters, such as the Preyer reflex and coat color, were variable among animals of the iso129X1 background. To evaluate the isogenicity of the background, we used the SNP panel developed at our institute to map mutant alleles from the genomewide Munich mutagenesis screen, as described in materials and methods. For this purpose, 15 wild-type and 18 heterozygous Dll1 lacZ mice from three different generations of our iso129X1 breeding colony were genotyped. Of the 137 SNP assays analyzed, 30% showed heterozygosity (data not shown). This is probably one of the main reasons for the variable phenotypes found by analyzing some parameters. The polymorphic genotype is most probably due to the backcrossing strategy of 129 substrains, which have a high degree of genetic variation (Simpson et al. 1997; Threadgill et al. 1997 ). Due to this fact, the nomenclature of the 129 substrains has been revised recently (Festing et al. 1999) .
Dysmorphological screen: We have screened .2200 F 1 animals in the search for modifiers of the Dll1 lacZ/1 phenotype (Table 3) . Due to the role of the Delta/ Notch pathway in the development of the mesoderm, we screened for morphological variants . Depending on the breeding strategy of the modifier genetic screen, 3.6% (26 animals derived from C57BL/6J mutagenized males) or 1.3% (four animals derived from iso129X1 mutagenized males) of the heterozygous Dll1 lacZ F 1 animals tested (see Table 3 ) showed variant phenotypes absent in their wild-type littermates and the Dll1 lacZ/1 reference population. The F 1 variants were backcrossed for testing the coinheritance of the phenotype with heterozygous Dll1 lacZ mice as described in Figure 1 . At present, seven of these confirmation crosses are still running, another seven have failed because the F 1 animals were sterile or died before the screen was finished, 12 variant phenotypes were not transmitted, and four were confirmed but were shown to be independent of the disruption of the Delta1 allele. All the mutant lines generated to this point are listed in Table 4 .The four Delta1-independent mutant lines generated in the dysmorphology screen display distinct phenotypes. A mutant line, SXR001, has been detected by performing X-ray analysis. In these animals one thoracic rib pair is missing. The other mutant phenotypes include alterations of coat shape such as curly coat (D1679) or coat length (BCC007) or reduction of the body weight (SWE001).
Immunological screen: The Notch signaling pathway plays a crucial role in the differentiation of lymphoid to B or T cells and within the abT cell lineage in differentiating to either helper or cytotoxic T cells (Allman et al. 2002; Radtke et al. 2004 Radtke et al. , 2005 . For this reason, we analyzed B-and T-cell markers in peripheral blood. A total of 960 heterozygous Dll1 lacZ F 1 animals have been screened at present (Table 3 ). In case of a variation in a parameter, the heterozygous Dll1 lacZ F 1 animal and its wild-type littermate were sampled a second time to confirm that presence of the variant phenotype was restricted to the heterozygous Dll1 lacZ mouse. Of the heterozygous Dll1 lacZ F 1 animals deriving from ENUmutagenized C57BL/6J males, 1.6% (11 animals) showed variant phenotypes absent in their wild-type littermates and the Dll1 lacZ/1 mice reference population. These included lower CD19-positive B-cell values and higher CD8-positive T-cell values. In addition, when analyzing F 1 animals derived from mutagenized Dll1 lacZ iso129X1, 5.3% (15 animals) showed an alteration of immunological parameters. Four confirmation crosses are still running, nine failed because the F 1 animal died B cells  32  SV7  TUB022  CD3 high, CD19 low  23  SV7  TUB023  CD8 high  70  SV7  TUB040  CD3 low  25  SV7  TUB046  CD19 low  43  129X1_DL1  TUB056  CD8 low  71  129X1_DL1  TUB059  DX5, CD8 high  58  SV7  TUB062  CD19 low  11  SV7  TUB063 CD19 low 50 129X1_DL1
a Only heterozygous animals were considered if transmitted only to Dll1 lacZ animals. b Remaining probability not to be a Dll1-dependent line is given by the binomial distribution.
before the screen was finished, one alteration was not transmitted, and one was transmitted, but its dependency on the disruption of the Delta1 locus still has to be determined. Nine were confirmed but were found not to be Delta1 dependent. However, two mutant lines showed a Delta1-dependent transmission of the phenotype (Table 3 ). The Delta1-independent mutant lines display a variety of phenotypes affecting immunological parameters. These include altered T-cell markers, such as in the mutant line TUB059; altered B-cell markers, such as in the mutant line TUB063; or alterations of both markers, such as in the mutant line TUB022 (Table 4) .
Of highest interest for our goal of identifying modifiers of the Notch signaling pathway are those lines that show co-inheritance of a variant phenotype only in the heterozygous Dll1 lacZ G 2 animals but not in their wildtype littermates. There is always a remaining probability for finding wild-type animals showing the observed phenotype. This probability (b) is dependent upon the penetrance of the phenotype and the number of wild-type animals screened and is given by the binomial distribution (see Table 4 ). As already mentioned, two immunological mutant lines that interact with the heterozygous Delta1 knockout allele have been established. 
/Dll1
lacZ/1 animals presented higher levels of CD8-positive T cells in blood. In this case, 3 of the 12 G 2 TUB060/Dll1 lacZ/1 animals screened showed the variant phenotype, whereas none of the 10 TUB60/Dll1 1/1 showed alteration of CD8-positive cell levels in blood. Both mouse lines show a penetrance of 50%; i.e., 25% of the heterozygous Dll1 lacZ G 2 animals show the phenotype. These lines are being further phenotypically characterized and backcrossed to the iso129X1 background. Intercrosses will further confirm the dependency of the phenotype on the disruption of the Delta1 locus.
Clinical chemical screen: Because the Notch signaling pathway is involved in numerous biological processes, we also screened for clinical chemical and hematological parameters, which provide a powerful diagnostic profile to detect defects in various organ systems and changes in numerous metabolic pathways. A total of 919 heterozygous Dll1 lacZ F 1 animals and 764 wild-type littermates have been screened so far (Table 3) . As mentioned in materials and methods, some parameters differ, depending on the genetic background or disruption of the Delta1 locus. These differences were taken into account when searching for variants. In case of a variation in a parameter, a second blood sample was taken 2 weeks later to confirm the phenotypic variation. For testing the inheritance of the phenotype with heterozygous Dll1 lacZ mice, 8.9% (60 of 672 animals) and 4% (10 of 247 animals) of the heterozygous Dll1 lacZ F 1 were backcrossed (Table 3) . Seventeen confirmation crosses are still running, 14 failed because the F 1 animals were sterile or died before the screen was finished, and 17 crosses showed no inheritance of the phenotype. Two variant phenotypes were inherited but the dependency on the disruption of the Delta1 locus still has to be determined. Fifteen variant phenotypes were confirmed but were Delta1 independent and five mutant lines showed a Delta1-dependent transmission of the phenotype. The Delta1-independent mutant lines established by investigating clinical chemical parameters cover distinct areas of metabolism and organ function (Table 4) , affecting pancreatic metabolism (SPA003 mutant line), cholesterol levels (SCO003 mutant line), liver metabolism (LIV002 mutant line), iron metabolism (SFR002 mutant line), and kidney function (D1534 mutant line). One line (D1379) has been established with altered basic hematological parameters. Most of the founders and mutant G 2 animals of all the established lines have been cryopreserved as described before (Marschall and Hrabe de Angelis 1999) for further analysis by the scientific community.
Of major interest are the five mutant lines where the clinical chemical parameters are altered only in conjunction with inheritance of one disrupted allele of the Delta1 locus. In the DCO001 mutant line, affected animals show higher plasma cholesterol levels. Of the 19 G 2 DCO001/Dll1 lacZ/1 animals screened, 4 showed the variant phenotype, whereas none of the 23 DCO001/ Dll1 1/1 showed alteration in the cholesterol levels. In the DFE001 and DFE002 mutant lines, the animals show alterations in plasma transferrin, ferritin, and/or iron levels. Of 19 G 2 DFE002/Dll1 lacZ/1 animals, 4 showed altered levels of transferrin in blood, whereas none of the 10 DFE002/Dll1 1/1 showed the phenotype. In the DLI001 mutant line, the animals show high aspartate aminotransferase activities. Of 45 G 2 DLI001/Dll1 lacZ/1 animals, 6 showed the pehnotype, whereas none of the 26 DLI001/Dll1 1/1 showed high aspartate aminotransferase activities. DLI001 1/À G 2 mutant animals were backcrossed to C57BL/6J, and the phenotype was recovered exclusively in heterozygous Delta1 mutant animals. Animals of the DTP001 mutant line show alterations in plasma creatinine, total protein, and electrolyte concentrations. In DTP001 1/À animals, the phenotype expressivity varies, showing high levels of creatinine, total protein, and/or electrolytes in blood. Of 15 G 2 DTP001/Dll1 lacZ/1 animals, 3 showed the phenotype, whereas none of the 8 DTP001/Dll 1/1 animals screened showed it. We backcrossed mutant G 2 animals to iso129X1 animals and only heterozygous Dll1 lacZ mutant animals showed either high total protein or high creatinine levels.
The DFE001 mutant line displays a complex phenotype, with animals showing altered values of transferrin, ferritin, and/or iron. Of the 24 G 2 DFE001/Dll1 lacZ/1 animals screened, 2 showed increased transferrin levels in blood and 5 showed increased iron levels, whereas none of the 7 G 2 DFE001/Dll1 1/1 animals screened showed alterations in any of these parameters. In Figure  3A the female Dll1 lacZ/1 mutant animals showing higher levels of iron in blood are depicted. These animals showed a Z-score of 3-4.9 of the iron levels. A similar effect was observed in male Dll1 lacZ/1 mutants; one of the compound mutants showed higher iron levels (Z-score ¼ 3.6) and the other higher transferrin levels in blood (Z-score ¼ 3.2). Moreover, only heterozygous Dll1 lacZ G 3 mice born from an intercross showed the mutant phenotype. As shown in Figure 3B , the ferritin levels were increased in three Dll1 lacZ/1 mutants showing a Z-score of 4-26 from the mean of the heterozygous Dll1 lacZ G 3 wild-type littermates. The other two Dll1 lacZ/1 mutant animals showed higher transferrin levels than their heterozygous Dll1 lacZ G 3 wild-type littermates, with a Z-score of 3.1 and 3.3 ( Figure 3C) . The later compound G 3 mutant also showed higher iron levels in blood (Z-score ¼ 3). We carried out a preliminary rough mapping of the mutation of DFE001, using our SNP platform mentioned above. Four G 2 Dll1 lacZ/1 mutant animals and five G 3 Dll1 lacZ/1 mutant animals were genotyped. The DFE001 mutation seems to show a linkage to the proximal region of the marker rs3663027 (57.5 Mb, Mus musculus genome build 36.1) on chromosome 2, with marker rs3022883 (37.5 Mb, M. musculus genome build 36.1) having only parental alleles, as shown in Figure  3D . Notch1 is located 11 Mb proximal to rs3022883. Therefore, this Notch receptor gene was the obvious candidate to sequence. We sequenced the coding region and exon/intron boundaries of Notch1 and no change compared to the parental sequence could be detected. Therefore, the DFE001 mutant line may reveal a novel modifier of Delta1 or the mutation could occur in a cisregulatory element of Notch1.
DISCUSSION
Role of genetic background in the Delta1 modifier screen: Modifiers of the Notch signaling pathway still need to be elucidated to explain all the biological functions and malfunctions in which this pathway is involved. Delta1 is one of the recognized ligands of Notch receptors. Thus we are carrying out a dominant modifier screen combining forward and reverse genetics to elucidate novel modifiers of Delta1 by mating ENU-mutagenized mice and heterozygous Dll1 lacZ mice. In our screen, both C57BL/6J and heterozygous Dll1 lacZ males were mutagenized with ENU and mated with females to generate F 1 animals. Mutagenesis of heterozygous Dll1 lacZ mice for the production of F 1 animals was less efficient than mutagenesis of C57BL/6J mice, as already described (Weber et al. 2000) . The reduced breeding performance of the iso129X1 background could be due to greater susceptibility to ENU if one allele of the Delta1 locus is missing. The reduced body weight may also contribute to the reduced fertility.
The genetic variation due to contamination of the 129X1/SvJ substrain, formerly named 129/SvJ, has recently been described in detail (Simpson et al. 1997; Threadgill et al. 1997) . Therefore, a genetic monitoring of the background was required and we determined genetic heterozygosity using a SNP panel.
Novel phenotypes in heterozygous Dll1 lacZ animals: Homozygous Dll1 lacZ animals die around embryonic day 12.5 (Hrabe de Angelis et al. 1997), and a homeotic transformation in the cervical region has been described in heterozygous Dll1 lacZ animals (Cordes et al. 2004 ). Here we showed that disruption of the Delta1 locus in one allele also leads to reduced body weight in the mutagenized offspring, regardless of age, gender, or background. Moreover, several clinical chemical parameters are also altered in mutagenized Dll1 lacZ/1 offspring. Chloride is significantly decreased in heterozygous Dll1 lacZ animals compared to their wild-type littermates. In addition, creatinine was decreased in blood in heterozygous animals regardless of gender. Both findings indicate that kidney metabolism is altered in these mice when compared to their littermates. Further analyses are required to understand the underlying mechanisms of these differences between heterozygous and wild-type mutagenized offspring.
Morphology and the Notch signaling pathway: Because the Notch signaling pathway plays a crucial role in morphogenesis, we screened for dysmorphological variations following a protocol that has been shown to be successful in our laboratory for identifying a broad range of morphological variations (Vreugde et al. 2002; Fitch et al. 2003; Hafezparast et al. 2003) . Although four mutant lines have been established in our screen, we have not yet found any dysmorphological variant whose phenotype was dependent on the disruption of the Delta1 locus. A possible explanation is the background used, 129X1/SvJ, which shows high variability in morphology; therefore we had to adapt our protocol. Other probable explanations are that the majority of mutants could be lethal during embryonic development due to the essential role of the Notch signaling pathway in the first days of development or that recessive modifiers are required to detect variations in the phenotype. Nevertheless, at least one exception has already been described. Heterozygous Dll1 lacZ mice have been shown to be an enhancer of the rib-vertebrae phenotype (Beckers et al. 2000) . Further studies revealed Tbx6 to be the gene mutated in this animal model (Watabe-Rudolph et al. 2002) and to be an interactor of the Notch signaling pathway, playing a major role in somitogenesis (White et al. 2003; Yasuhiko et al. 2006) . Certainly more modifiers of the Notch signaling pathway could affect morphology. We will therefore carry on our screen focusing on bone alterations. Cell culture studies indicate a role of the Notch signaling pathway in bone morphogenesis, but with contradictory proposed functions. Some postulate inhibition of osteoblastogenesis (Deregowski et al. 2006) and others induction of osteoblast differentiation (Nobta et al. 2005) .
Immunological phenotypes of the Notch signaling pathway: Notch signaling plays a major role in cell-fate decision in the immune system, mainly in T-cell differentiation and activation (Allman et al. 2002; Radtke et al. 2004 Radtke et al. , 2005 Tsukumo and Yasutomo 2004) . Conditional ablation of floxed Notch1 alleles, induced by interferon-regulated creatinine-recombinase expression, produced an increase of B cells and a decrease of T cells in the thymus (Radtke et al. 1999; Wilson et al. 2001) . In contrast, conditional disruption of the Delta1 locus in lymphoid tissue revealed an unexpected phenotype, having no effect on T cells but an effect on the generation of marginal B cells (Hozumi et al. 2004) . A more recent study has shed further light on the effect of Notch signaling, showing that it can influence the differentiation of immature thymocytes into the NK cell and gdT-cell lineages during a brief window of development between the DN1 and DN3 stages (Lehar et al. 2005) . Therefore, different questions still have to be resolved to explain the mechanism of cell fate in the immune system. In our screen we successfully identified two compound mutant lines in which the immunological phenotype was dependent on the disruption of the Delta1 locus and the presence of an ENU mutation. Interestingly, both lines show alterations in lymphocyte development in blood or in T-cell maturation. Both derived from independent ENU-injected males, and therefore most probably harbor different mutations. These lines will provide a powerful in vivo tool to investigate cell-fate decision in the immune system.
Novel metabolic phenotypes of the Notch signaling pathway: Studies of Delta1 expression in adulthood are scarce. In mice, Delta1 expression has been detected by Northern blot in heart and lung (Bettenhausen et al. 1995) and in humans faintly in several tissues such as heart, lung, kidney, and muscle (Gray et al. 1999) . Moreover, information about the role of Delta1 in adulthood is scarce, and no disease has yet been linked to this ligand (Harper et al. 2003) . We searched for modifiers of Delta1 by screening for clinical chemical parameters, which provide a powerful diagnostic tool to detect defects resulting in alterations of various organ systems and changes in numerous metabolic pathways. As mentioned before, 21 mutant lines that demonstrate again the effectiveness of the screen have been established. More interesting for our purpose are the 5 mutant lines established that show phenotypes that are dependent on the presence of a disrupted copy of the Delta1 gene. The phenotypes cover different aspects of metabolism. A link between cholesterol and Delta1 may be explained by the a-secretase ADAM10. ADAM10-deficient mice die at embryonic day 9.5, and these mice showed a higher expression of Delta1 (Hartmann et al. 2002) . On the other hand, cell culture studies have demonstrated that low cholesterol levels promote the nonamyloidogenic pathway by increasing ADAM10 expression (Kojro et al. 2001) . Further analysis is required to investigate why cholesterol levels are higher in the DCO001 mutant animals and which kind of interaction exists with Delta1. The DLI001 mutant animals show higher levels of AST in blood. AST is usually elevated in blood in response to liver tissue damage. This effect is most probably secondary to another dysfunction and therefore more animals will be required for further analyses. Interesting are alterations in kidney metabolism; as already mentioned, only one electrolyte and creatinine levels seem to be altered in heterozygous Dll1 lacZ mice regardless of background or gender. Notch signaling plays a key role in kidney development and repair of tissue damage, but genes other than Delta1 seem to be involved in this process, too, such as Notch2 and Jagged1 (McCright 2003) . Nevertheless, Delta1 is expressed in kidney and our screen has provided a mutant line, DTP001, where a potential modifier of Delta1 induces an increase of creatinine and other kidney metabolites in blood. Clarifying which ENU-mutated gene is responsible for this phenotype will help to elucidate the role of Delta1 in the kidney in adulthood. The role of Notch signaling in iron metabolism is not known. We have established two compound mutant lines with alterations in iron metabolites. DFE001 animals have a mutation that leads to modification of the heterozygous phenotype increasing ferritin levels in blood. We preliminary mapped the mutation to chromosome 2, but Notch1 does not seem to be the mutated gene. Therefore, DFE001 may reveal a novel modifier of the Notch signaling pathway or the mutation could occur in a cis-regulatory element of Notch1. Moreover, 31 confirmation crosses that will deliver more interesting mutant lines are still running.
Conclusion: Here we present the mutagenesis screens running at our laboratory using Delta1 heterozygous animals with the main focus on searching for modifiers of the Notch signaling pathway. We have shown that heterozygous Dll1 lacZ -mutagenized offspring show a reduction of body weight and alterations in clinical chemical parameters compared to their wild-type littermates. We have established 35 mutant lines that consolidate the genomewide mutagenesis project that has been run at our laboratory for several years. Of major interest are the 7 new mutant lines that might reveal new modifiers of the Notch signaling pathway. Therefore, new mouse models have been established to understand the role of Notch signaling in liver, kidney, iron, and cholesterol metabolism and in cell-fate decision in adulthood in the immune system.
